# Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Source: https://onco.cc/trials/nct05733598/  
OnCo record `nct05733598` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bevacizumab, Atezolizumab, Durvalumab in hepatocellular carcinoma, run by Replimune, Inc., now recruiting.

## Summary

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC is a phase 2 interventional study registered as NCT05733598 by Replimune, Inc., with 60 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05733598
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma
- Sponsor: Replimune, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05733598: https://clinicaltrials.gov/study/NCT05733598

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct05733598.json